Patents by Inventor John Desjarlais

John Desjarlais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20200165356
    Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
    Type: Application
    Filed: April 4, 2019
    Publication date: May 28, 2020
    Inventors: John Desjarlais, Alex Nisthal, Seung Chu
  • BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
    Publication number: 20200123259
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 23, 2020
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Fc variants with increased affinity for Fc?RIIc
    Patent number: 10584176
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 10, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • HETERODIMERIC PROTEINS
    Publication number: 20200048370
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 13, 2020
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
    Publication number: 20200040083
    Abstract: The present invention is directed to novel IL15/IL15R? heterodimeric Fc fusion proteins.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 6, 2020
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Bispecific heterodimeric fusion proteins containing IL-15-IL-15R? Fc-fusion proteins and PD-1 antibody fragments
    Patent number: 10550185
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: February 4, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Targeting regulatory T cells with heterodimeric proteins
    Patent number: 10544187
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 28, 2020
    Assignee: Xencor, inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 10526417
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 7, 2020
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • Targeting regulatory T cells with heterodimeric proteins
    Patent number: 10519242
    Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 31, 2019
    Assignee: Xencor, Inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
    Publication number: 20190389954
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
  • PD-1 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15Ra Fc-FUSION PROTEINS AND PD-1 ANTIGEN BINDING DOMAINS AND USES THEREOF
    Publication number: 20190389933
    Abstract: The present invention is directed to novel PD-1-targeted IL-15/R?-Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/R?-Fc fusion proteins can be administered to a patient to treat cancer.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 26, 2019
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
    Publication number: 20190382495
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 19, 2019
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
  • IL15/IL15R? heterodimeric Fc-fusion proteins
    Patent number: 10501543
    Abstract: The present invention is directed to novel IL15/IL15R? heterodimeric Fc fusion proteins.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: December 10, 2019
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • IL-15/IL-15RA HETERODIMERIC FC FUSION PROTEINS AND USES THEREOF
    Publication number: 20190365861
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 5, 2019
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
    Publication number: 20190359684
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: April 18, 2019
    Publication date: November 28, 2019
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • Heterodimeric proteins
    Patent number: 10487155
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 26, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
    Publication number: 20190352362
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: April 18, 2019
    Publication date: November 21, 2019
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • TRISPECIFIC ANTIBODIES
    Publication number: 20190352416
    Abstract: Provided herein are trispecific antibodies that include a) a first monomer, b) a second monomer, and c) a light chain. The first monomer includes a first variant Fc domain and a variable heavy domain, the second monomer includes a second variant Fc domain and a first scFv domain and the light chain includes a variable light domain. The variable heavy domain and the variable light domain form an antigen binding domain. The trispecific antibody further includes a second scFv domain on either the first or second monomers.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 21, 2019
    Inventors: Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
  • Heterodimeric proteins
    Patent number: 10472427
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 12, 2019
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
  • Trispecific antibodies
    Patent number: 10428155
    Abstract: The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: October 1, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee